Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, July 21, 2026, 11:00-11:30 AM CT
Roundtable presenters Nick Fingland, PhD, PMP, Senior Director, R&D Operations and Science, BD, and Chris Farnsworth, PhD, D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 29, 2026, 1:00-2:00 PM ET
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.
Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center-Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center-Department of Pathology.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2026—A six-year-old boy presented with abdominal pain and was found to have a large mediastinal mass. Biopsy revealed a spindle cell sarcoma, and molecular testing identified an NTRK1 rearrangement, confirming the diagnosis of NTRK1-rearranged spindle cell sarcoma.
February 2026—Cybersecurity and image management are key concerns for laboratories adopting digital pathology and AI. While cloud-based systems offer enhanced security and scalability, onboarding new vendors and instruments remains challenging due to stringent security requirements and potential vulnerabilities.
February 2026—CAP TODAY publisher Bob McGonnagle spoke on Dec. 2, 2025 with Steve Swartzell and Scott Johnston of ELITechGroup. McGonnagle’s questions and their answers follow. A few of the questions came from the roundtable audience and are identified as such.
Bob McGonnagle: Steve, how long have you been with ELITech and what is your background in molecular diagnostics?
Steve Swartzell: I am director of customer experience and have been with ELITechGroup for 22 years. My background is in microbiology. I started as a research scientist in R&D and I was an application specialist working directly with customers. I have many years of lab experience as well. Now I oversee all the field activities for ELITechGroup MDx in the U.S. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by ELITechGroup.
January 2026—When new biomarkers become part of clinical practice, the fundamental question—Will this work?—soon gives way to an equally important group of interrogatives: who, what, when, where, why, and how. At Michigan Medicine, introducing two biomarkers—glial fibrillary acidic protein, or GFAP, and ubiquitin C-terminal hydrolase L1, or UCH-L1—into the emergency department to evaluate traumatic brain injury emphasized the how of the matter.
January 2026—For Jansen Seheult, MD, and others deeply committed to bringing artificial intelligence to the laboratory, it’s impossible to deny that algorithm development has advanced by leaps and bounds. Take Mayo Clinic in Rochester, where Dr. Seheult is medical director of digital pathology and artificial intelligence in hematopathology. More than 20 artificial intelligence algorithms are deployed across the clinical practice in pathology and laboratory medicine. Yet that’s a small fraction of all the algorithms that have been developed at the clinic.
January 2026—Translating cytokine science into better cancer care was the focus of a presentation at last year’s ADLM meeting, where the toxicities associated with CAR T-cell therapy were explained with cases and the need to measure cytokines was made clear.
January 2025—In the 2025 edition of the CAP accreditation checklists are new requirements on humidity, specimen self-collection, body fluid crystal analysis, and pneumatic tube transport of blood specimens for platelet aggregation or other platelet function testing. The new checklist edition was released last year on Dec. 9.
January 2026—Based on the results of Destiny-PanTumor02,1 targeted HER2-based therapies are now available as treatment options agnostic of tumor type. As oncologists seek to offer these targeted therapies to the patients likely to benefit, many laboratories have had to determine how best to expand the use of existing HER2 assays. At the same time, other laboratories may now see testing volumes increasing to justify new validation.
January 2026—The Association for Diagnostics and Laboratory Medicine released new guidance discouraging clot-based testing in patients receiving direct oral anticoagulants (DOACs).
December 2025—Bringing next-generation sequencing (NGS) in-house can be approached in two ways: a rapid, comprehensive implementation or a gradual, progressive build. Florida Cancer Specialists opted for a rapid approach, starting with a complex pancancer solid tumor panel, which facilitated the addition of smaller assays.
